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Background and Purpose:

Both innate immunity and the renin‐angiotensin system

(RAS) play important roles in the pathogenesis of diabetic nephropathy (DN). Myeloid
differentiation factor 2 (MD2) is a co‐receptor of toll‐like receptor 4 (TLR4) in innate
immunity. While TLR4 is involved in the development of DN, the role of MD2 in DN
has not been characterized. It also remains unclear whether the MD2/TLR4 signalling
pathway is associated with RAS activation in diabetes.
Experimental Approach:

MD2 was blocked using siRNA or the low MW inhibitor,

L6H9, in renal proximal tubular cells (NRK‐52E cells) exposed to high concentrations of glucose (HG). In vivo, C57BL/6 and MD2−/− mice were injected with
streptozotocin to induce Type 1 diabetes and nephropathy.
Key Results:

Inhibition of MD2 by genetic knockdown or the inhibitor L6H9 sup-

pressed HG‐induced expression of ACE and angiotensin receptors and production of
angiotensin II in NRK‐52E cells, along with decreased fibrosis markers (TGF‐β and collagen IV). Inhibition of the MD2/TLR4‐MAPKs pathway did not affect HG‐induced
renin overproduction. In vivo, using the streptozotocin‐induced diabetic mice, MD2
was overexpressed in diabetic kidney. MD2 gene knockout or L6H9 attenuated renal
fibrosis and dysfunction by suppressing local RAS activation and inflammation.
Conclusions and Implications:

[Correction added on 6 January, after first
online publication: Funding Information has
been corrected in this current version.]

Hyperglycaemia activated the MD2/TLR4‐MAPKs

signalling cascade to induce renal RAS activation, leading to renal fibrosis and dysfunction. Pharmacological inhibition of MD2 may be considered as a therapeutic
approach to mitigate DN and the low MW inhibitor L6H9 could be a candidate for
such therapy.

1

|

I N T RO D U CT I O N

local RAS is one of the major pathogenetic factors in diabetic nephropathy (DN). Renal RAS is activated in DN along with an elevated pro-

There is evidence for an important role for the renin‐angiotensin sys-

duction of local angiotensin II (Ang II; Roscioni, Heerspink, & de

tem (RAS) in the pathogenesis of diabetic complications. Activation of

Zeeuw, 2014; Ruster & Wolf, 2006; Zain & Awan, 2014). Ang II, which
binds its classic membrane receptor, the AT1 receptor, was originally

Abbreviations: Ang II, angiotensin II; DM, diabetes mellitus; DN, diabetic nephropathy; HG,

identified as a vasoactive peptide that constricts the afferent and

high glucose; KO, knockout; MD2, myeloid differentiation factor 2; RAS, renin‐angiotensin

the efferent arterioles as well as the interlobular arteries, causing

system; STZ, streptozotocin
Yi Wang, Qilu Fang, and Yiyi Jin contributed equally to this work.

2642

© 2019 The British Pharmacological Society

reduced renal blood flow, increased intraglomerular pressure, and
increased GFR (Denton, Fennessy, Alcorn, & Anderson, 1992). Local
wileyonlinelibrary.com/journal/bph
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Ang II also functions as a growth factor activating interstitial and tubular fibrosis (Singh, Alavi, Singh, & Leehey, 1999) and triggers inflamma-

What is already known

tion through promoting production of inflammatory cytokine and

• Both innate immunity and renin‐angiotensin system play

adhesion molecules (Vaziri et al., 2007). Furthermore, RAS blockade

important

through either inhibition of renin and ACE or AT1 receptor antagonists

roles

in

the

pathogenesis

of

diabetic

nephropathy.

exhibits beneficial effects against DN (Barnett et al., 2004). Despite

• TLR4 has been reported to mediate inflammatory

the critical role of activated local RAS in DN, the local regulation of

diabetic nephropathy.

each component by hyperglycaemia has not been fully clarified.
Current anti‐RAS therapies for the treatment of DN focus on the

What this study adds

inhibition/antagonism of ACE or AT1 receptors, but few studies have

• Blockade of MD2 attenuates diabetic nephropathy by

been performed to understand the upstream mechanism and targets

suppressing local RAS activation and inflammation.

that mediate the up‐regulation of renal ACE/AT1 receptor expression
under the condition of hyperglycaemia. It remains poorly understood

• Hyperglycaemia induces renal ACE/AT1 expression and

how hyperglycaemia activates local RAS and increases local Ang II

Ang II production via activating MD2/TLR4‐MyD88‐

level in kidney.

MAPKs signalling cascade.

Using some specific low MW inhibitors, we previously demonstrated that the MAPKs signalling pathway could regulate ACE

What is the clinical significance

expression in renal proximal tubular NRK‐52E cells under high glucose

• Pharmacological inhibition of MD2 is a potential
therapeutic approach for diabetic nephropathy.

(HG) stimulation, which contributed to the increase in renal Ang II
level and the development of DN (Pan et al., 2014). In innate immunity, activation of MAPKs was associated with the toll‐like receptor
4 (TLR4) signalling pathway. TLR4, together with its co‐receptor myeloid differentiation factor 2 (MD2), is essential for the response of the

humidified atmosphere of 95% air and 5% CO2 at 37°C. In the nor-

innate immunity system to LPS. Activated MD2/TLR4 recruits its

mal and control cell culture, the NRK‐52E cells were incubated with

downstream factor MyD88 to activate MAPKs signalling pathways,

5.5‐mM glucose. When cells were exposed to HG conditions, the

leading to production of inflammatory cytokines (Kawai & Akira,

cells were incubated with 33‐mM glucose.

2006). In addition, recent studies have demonstrated that TLR4 plays
an important role in the pathogenesis of DN (Verzola et al., 2014; Wada
& Makino, 2016). TLR4 activation promotes renal inflammation,

2.2

|

Real‐time quantitative PCR

podocyte and tubular epithelial cell injury, and interstitial fibrosis,
and TLR4−/− mice were protected against the development of DN

Cells or kidney tissues (80–100 mg) were homogenized in TRIZOL

(Ma et al., 2014). However, the role of MD2 in DN has not been

(Invitrogen, Carlsbad, CA, USA) for extraction of RNA according to each

characterized, and it remains unclear whether diabetes‐induced RAS

manufacturer's protocol. Both reverse transcription and quantitative

activation including ACE/ AT1 receptor expression and Ang II produc-

PCR were carried out using a two‐step M‐MLV Platinum SYBR Green

tion is associated with the TLR4 or the MD2/TLR4 signalling pathways.

qPCR SuperMix‐UDG kit (Invitrogen). Eppendorf Mastercycler realplex

Based on this analysis, we hypothesized that activation of

detection system (Eppendorf, Hamburg, Germany) was used for qPCR

MD2/TLR4 by hyperglycaemia may induce local RAS activation and

analysis. The primers of genes used here were obtained from Invitrogen

Ang II production, via an MAPK‐dependent manner. In this study, using

(Shanghai, China) and the primer sequences are listed in Table S1.

pharmacological and genetic interventions both in vitro and in vivo, we

For in vitro samples, each treatment condition was run in triplicate

characterized the role of MD2/TLR4‐MAPKs in hyperglycaemia‐

(technical replicates). The same experiment was independently

mediated local RAS activation and renal fibrosis in a model of Type 1

repeated for five times. Gene expression was normalized to β‐actin

diabetes and found that blockade of MD2 significantly attenuated DN

mRNA levels in the same sample and then normalized to the average

via reducing renal RAS activation.

value of the control group in each experiment according to the 2−ΔΔCt
algorithm. Data represented five independent experiments and
expressed as means ± SEM. Since we calculated the ΔCT value in each

2

METHODS

|

experiment independently, the means ± SEM of the relative ΔCt
values of the control group is 1.0 ± 0.0 (n = 5). However, when we per-

2.1

|

Cell culture

formed the statistical analysis, we put the original data in five‐time
qPCR experiments together, and the gene expression was normalized

NRK‐52E cells were obtained from the Shanghai Institute of

to β‐actin mRNA levels in the same sample and was then normalized

Biochemistry and Cell Biology (Shanghai, China) and cultured in

to the ΔCt value of the control group in the first‐time repeat.

DMEM medium (Gibco, Eggenstein, Germany) containing 10% FBS,

For in vivo samples, the qPCR analysis of the kidney tissues

100 U·ml−1 of penicillin, and 100 mg·ml−1 of streptomycin in a

from seven mice were performed together (in one plate). The gene

2644
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expression was normalized to β‐actin mRNA levels in the same sample

Male C57BL/6 mice (totally n = 70) weighing 18–22 g were

and was then normalized to one randomly selected mouse in control

obtained from Animal Center of Wenzhou Medical University. Whole

group according to the 2−ΔΔCt algorithm.

body MD2 knockout (KO) mice (B6.129P2‐Ly96 KO, MD2−/−) on
C57BL/6 background (n = 16) were purchased from Riken

2.3

|

Western blotting

BioResource Center (Tsukuba, Ibaraki, Japan; RRID:SCR_003250)
and maintained in the Animal Centre of Wenzhou Medical Univer-

The antibody‐based procedures used in this study comply with the

sity. Animals were housed at a constant room temperature with a

recommendations made by the British Journal of Pharmacology.

12:12 hr light–dark cycle and were fed with water and a standard

Collected cells or homogenized kidney tissue samples were lysed.

rodent diet containing 10‐kcal.% fat, 20‐kcal.% protein, and

Lysates (50–80 μg) were separated by 10% or 12% SDS‐PAGE and

70‐kcal.% carbohydrate (MediScience Diets Co. LTD, Yangzhou,

electrotransferred to nitrocellulose membranes. The membranes were

China, Cat. #MD12031). The animals were acclimatized to the

pre‐incubated for 1.5 hr at room temperature in Tris‐buffered saline,

laboratory for at least 2 weeks before initiating the studies. All

pH 7.6, containing 0.05% Tween 20 and 5% non‐fat milk. The

animal experiments were performed and analysed by blinded

membrane was then incubated with specific antibodies. Immunoreac-

experimenters. Treatment groups were assigned in a randomized

tive bands were detected by incubating with secondary antibody

fashion. Each mouse was assigned a temporary random number

conjugated with HRP and were visualized using enhanced chemilumi-

within the weight range. When mice were randomly divided in each

nescence reagents (Bio‐Rad, Hercules, CA, USA). The bands were

group, they were given their permanent numerical designation in the

analysed using Image J analysis software version 1.38e (RRID:

cages. For each group, a cage was selected randomly from the pool

SCR_003070) and normalized to their respective controls.

of all cages.

2.4

|

Immunoprecipitation

Lysates (300–500 μg) were incubated with anti‐MD2 or anti‐TLR4
antibodies for 1 hr. Proteins were immunoprecipitated with protein
G‐Sepharose beads on a shaker at 4°C overnight. The supernatants
were used for the detection of TLR4 or MyD88as co‐precipitated
proteins, respectively, using western blotting. The density of the
immunoreactive bands was analysed using Image J software (NIH,
Bethesda, MD).

To induce Type 1 diabetes, WT, and MD2−/− mice were treated
with a single i.p. injection of streptozotocin (STZ; 100 mg·kg−1 in citrate buffer, pH 4.5), while the control animals were received the same
volume of citrate buffer. The blood glucose level was monitored using
a glucometer after 4 hr of fasting. One week after STZ injection,
mice with fasting‐blood glucose >2.16 g·l−1 were considered as diabetic. The DN was developed in 2–4 months after STZ‐induced
hyperglycaemia.
1. For MD2/TLR4 expression analysis, 14 C57BL/6 mice were
treated with STZ injection to induce hyperglycaemia and then
were fed with standard diet for 2 or 4 months, randomly, to

2.5

|

siRNA‐induced gene silencing

develop nephropathy. Seven control mice were received the same
volume of citrate buffer. Two months after STZ injection, seven

Silencing gene expression was achieved using the siRNA technique.

STZ‐injected mice (STZ [2 M]) were killed using sodium pentobar-

MD2 or MyD88 siRNAs were purchased from Gene Pharma (Shanghai,

bital anaesthesia. Four months after STZ injection, seven control

China). Transfection of NRK‐52E cells with siRNA was carried out using

mice (Ctrol) and seven STZ‐injected mice (STZ [4 M]) were killed

LipofectAMINE™ 2000 (Invitrogen, Carlsbad, CA), according to the

using sodium pentobarbital anaesthesia (i.p. injection of 0.2‐ml

manufacturer's instruction. Some of the transfected cells were then

sodium pentobarbital at 100 mg·ml−1).

treated with HG for the further experiments. Specific siRNA sequences

2. For MD2 deficiency analysis, 24 C57BL/6 mice and 16 MD2−/−

were 5′‐CCAUCAUUCACCACCAUAATT‐3′ and 3′‐UUAUGGUGGUG

mice were randomly divided into five groups as WT‐Control,

AAUGAUGGTT‐5′ for rat MD2 and 5′‐GGAAUGUGACUUCCAGACC

WT‐diabetes mellitus (DM), WT‐DM + Val, KO‐Control, and KO‐

TT‐3′ and 3′‐GGUCUGGAAGUCACAUUCCTT‐5′ for rat MyD88.

DM (n = 8 in each group) respectively. The randomized animal division results in five treatment groups in total. Mice in WT‐DM, WT‐

2.6

|

Animal experiments

DM + Val, and KO‐DM were treated with STZ injection to induce
hyperglycaemia for 1 week and then were fed with standard diet

All animal care and experimental procedures were approved by the

for 15 weeks to develop nephropathy. Mice in WT‐Control and

Wenzhou Medical University Animal Policy and Welfare Committee

KO‐Control were received the same volume of citrate buffer. In

(Approval Document No. wydw2016‐0124), and all animals received

WT‐DM + Val group, STZ‐induced diabetic mice were orally

humane care according to the National Institutes of Health (USA)

treated with valsartan (30 mg·kg−1 per 2 days) for 15 weeks. Body

guidelines. Animal studies are reported in compliance with the ARRIVE

weight and blood glucose were recorded weekly. Sixteen weeks

guidelines (Kilkenny et al., 2010; McGrath, Drummond, McLachlan,

after STZ injection, animals were killed using sodium pentobarbital

Kilkenny, & Wainwright, 2010) and with the recommendations made

anaesthesia (i.p. injection of 0.2‐ml sodium pentobarbital at

by the British Journal of Pharmacology.

100 mg·ml−1).
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3. For L6H9 treatment analysis, 32 C57BL/6 mice (four groups, n = 8
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Immunofluorescent double staining

|

per group) were used. One week after STZ injection, 24 mice with
fasting‐blood glucose >216 mg·dl−1 were considered as diabetic.

For immunofluorescent double staining, frozen sections (5 μm) of

The control animals (n = 8) were received the same volume of cit-

renal tissues were washed three times with PBS at room temperature

rate buffer. Randomly selected diabetic animals were divided into

and each wash was carried out for 5 min. Slides were blocked using

three groups: DM (n = 8), curcumin‐treated DM (DM + Cur,

5% BSA for 30 min and then incubated overnight at 4°C with both

n = 8), and L6H9‐treated DM (DM + L6H9, n = 8). In the DM + Cur

MD2 antibody and antibody of specific marker (anti‐WT1 from Novus;

−1

group and DM + L6H9 group, curcumin (50 mg·kg ) and L6H9

anti‐AQP1 from Santa Cruz; anti‐F4/80 from Abcam) respectively.

(20 mg·kg−1) were administered as oral gavage once every 2 days

Slides were then correspondingly incubated with two kinds of second-

respectively. The DM group and age‐matched control group

ary antibody (TRITC labelled antibody from Abcam) at 37°C for 1 hr

(n = 8) received 1% CMC‐Na solution alone according to the same

and washed four times with PBS. DAPI was used to stain nuclei for

schedule. The randomized animal division results in four treatment

10 min and all stained sections were viewed by fluorescence confocal

groups in total. Body weight and blood glucose levels were

microscopy (Nikon).

recorded weekly. After 8 weeks of treatment, animals were killed
under sodium pentobarbital anaesthesia (i.p. injection of 0.2‐ml
sodium pentobarbital at 100 mg·ml−1).

2.9

Data and statistical analysis

|

All experiments were randomized and blinded. The data and statistical
At 6 hr before killing, the spontaneous urine was collected using
the following method: (a) the mouse was placed in a clean, dry, and
empty cage and allowed to roam around; (b) the mouse is returned
to its home cage and the urine was aspirated using a pipette and transferred to a collection tube as soon as the mouse urinates. Blood and
renal tissues were collected at the time of killing. The body weight
and right kidney weight were recorded. Serum creatinine, urinary
albumin, and urinary creatinine were detected using commercial kits
(Nanjing Jiancheng, Jiangsu, China). The kidney tissues from all animals
were fixed in 4% paraformaldehyde for paraffin embedding and
histopathological analysis or were snap‐frozen in liquid nitrogen for
gene and protein expression analysis. The fixed kidney tissues were

analysis comply with the recommendations of the British Journal of
Pharmacology on experimental design and analysis in pharmacology
(Curtis et al., 2015). In all in vitro experiments, data represented five
independent experiments and expressed as means ± SEM. Statistical
analysis was performed with GraphPad Prism 6.0 software (San Diego,
CA, USA; RRID:SCR_002798). We used one‐way ANOVA followed by
Dunnett's post hoc test when comparing more than two groups of
data and one‐way ANOVA, non‐parametric Kruskal–Wallis test,
followed by Dunn's post hoc test when comparing multiple independent groups. P values of ˂.05 were considered to be statistically significant. Post‐tests were run only if F achieved P < .05 and there was no
significant variance in homogeneity.

sectioned at 5‐μm thickness. The sections were stained with
haematoxylin and eosin for histopathological analysis. The slides were
examined under light microscope (400× amplification; Nikon, Japan).
Paraffin sections (5 μm) of the kidney tissues were stained using
Masson's three‐colour staining kit, PAS, or sirius red staining kits
(Beyotime Biotechnology, Nantong, China), respectively, according to
the manufacturer's instructions. The slides were examined under light
microscope (400× amplification; Nikon). To quantify the level of fibrosis in Masson staining or collagen deposition in sirius red staining, the
Image J software (NIH) was used and 10 non‐overlapping fields in
each tissue (n = 8) were scored on a semi‐quantitative scale (<5%,
5–10%, 10–25%, 25–50%, 50–75%, and 75–100%), relative to total
tissue area in the field. For PAS scoring, semi‐quantitatively on
30–50 glomeruli per kidney in each group (n = 8), using a scale from

2.10

|

Materials

Glucose, mannitol, STZ, valsartan, and curcumin were purchased from
Sigma (St. Louis, MO). SB203580 (SB), SP600125 (SP), and PD98059
(PD) were purchased from Beyotime Biotechnology. The MD2 inhibitor L6H9, synthesized by our lab, with a purity of 98.9%, was dissolved in DMSO for in vitro experiments and was dissolved in 1%
CMCNa for in vivo experiments. Antibodies for GAPDH, p‐IκBα, IκBα,
p‐ERK, ERK, ACE, TGF‐β, collagen 4, TLR4, MD2 (RRID:AB_2138097),
MyD88, MMP2, Bcl‐2, Bax, and CD68 were purchased from Santa
Cruz (Santa Cruz, CA); and p‐JNK, JNK, p‐p38, TNF‐α, and p38 antibodies were obtained from Cell Signaling (Danvers, MA).

0 to 4 score for description: 0 indicates no mesangial matrix expansion, 1 for minimal, 2 for mild, 3 for moderate, and 4 for diffuse.

2.11

|

Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to

2.7

|

Ang II assay

corresponding

entries

in

http://www.guidetopharmacology.org,

the common portal for data from the IUPHAR/BPS Guide to PHARThe Ang II levels in cell culture medium, mouse serum, or kidney tissue

MACOLOGY (Harding et al., 2018), and are permanently archived in

lysates were determined using an ELISA kit (Bioscience, San Diego,

the Concise Guide to PHARMACOLOGY 2017/18 (Alexander,

CA) according to the manufacturer's instructions. The amount of Ang

Christopoulos et al., 2017; Alexander, Fabbro et al., 2017a, b; Alexander,

II was normalized to the total amount of protein in the same group.

Kelly et al., 2017a, b).
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under HG conditions (Figure 1b), the HG‐induced elevations of
ACE and AT1 receptors were prevented in the MD2 knockdown

3.1 | MD2 silencing attenuated HG‐induced RAS
activation and TGF‐β expression

cells (Figure 1c–e). Si‐MD2 further decreased HG‐induced increased
Ang II secretion into the cell culture medium (Figure 1f). The protein
and mRNA analysis further showed that Si‐MD2 suppressed

In diabetic kidney, Ang II secretion and RAS activation have been

HG‐induced overexpression of TGF‐β (Figure 1c,g). As expected,

reported to occur mainly in renal tubular cells (Vallon & Thomson,

the osmotic control, 33‐mM mannitol, did not affect TGF‐β gene

2012). HG stimulates the expression of angiotensinogen, the precur-

transcription (Figure 1b–f). Taken together, these data demonstrated

sor of Ang II in the proximal tubular epithelial cells (Feliers & Kasinath,

that MD2 silencing attenuates HG‐induced RAS activation and

2010). To investigate whether MD2/TLR4 participates in the activa-

TGF‐β expression.

tion of the RAS induced by HG, we first performed MD2 knockdown
experiment by using MD2 siRNA (Si‐MD2) in renal proximal tubular
NRK‐52E cells. Figure 1a shows that 80% of MD2 expression was
decreased after siMD2 treatment in NRK‐52E cells. MD2 knockdown

3.2 | The MD2 inhibitor L6H9 suppressed
HG‐induced RAS activation and TGF‐β expression
through inhibition of TLR4/MyD88 signalling pathway

and control cells were subsequently incubated in medium with HG
(33 mM) for 12 hr. HG increased the expression of genes involved in

Next, we used compound L6H9 (Figure 2a), a specific, low MW inhib-

the RAS in NRK‐52E cells (Figure 1b–f). The expression of genes in

itor of MD2 that blocked palmitic acid‐induced activation of

the RAS was not affected by treatment with 33‐mM mannitol, indicat-

MD2/TLR4 in cardiomyocytes (Wang et al., 2017), to further confirm

ing that the osmotic effect did not induce RAS activation in renal cells

these findings. Curcumin, a natural anti‐inflammatory compound

(Figure 1b–f). Although Si‐MD2 did not affect the renin expression

which is known to inhibit activation of MAPKs by HG (Fang et al.,

FIGURE 1 MD2 silencing attenuated the activation of the RAS, induced by high glucose concentrations. (a) MD2 knockdown in NRK‐52E cells
by siRNA approach. Two si‐RNA sequences for MD2 gene (Si‐MD2) were transfected in NRK‐52E cells and the MD2 protein levels were
measured by western blot analysis (Ctrol: non‐transfected cells; NC: non‐MD2 scrambled transfection cells; two different siRNAs for MD2 were
used). (b–g) Effects of MD2 knockdown in macrophages stimulated by high glucose concentrations (HG; 33 mM) (b, d, e, and g) Si‐RNA transfected
or NC NRK‐52E cells were incubated with HG or 33‐mM mannitol for 12 hr. The mRNA levels of renin, ACE, AT1 receptors (AT1) and TGF‐β were
detected by real‐time quantitative PCR assay with β‐actin used as housekeeping gene. (c and f) Si‐RNA transfected or NC NRK‐52E cells were
incubated with HG or 33‐mM mannitol for 24 hr. Shown are representative western blot analysis and densitometric results for ACE and TGF‐β
protein levels in whole cell lysate with GAPDH as a loading control. Ang II level in cultured medium was detected by ELISA kit. n = 5 independent
experiments; bar graph shows mean values ± SEM; #P < .05, significantly different from NC group; *P < .05, significantly different from HG group;
ns = not significantly different from NC + HG group
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FIGURE 2 L6H9 suppressed HG‐induced MD2/TLR4‐MAPKs signalling and RAS activation. (a) Chemical structure of the MD2 inhibitor L6H9.
(b–c) L6H9 suppressed the activation of MD2/TLR4/MyD88 signalling. (b) NRK‐52E cells were pretreated with L6H9 (10 μM) for 1 hr, followed
by incubation with high glucose concentrations (HG; 33 mM) for 5 min, and cells were collected for co‐immunoprecipitation analysis. (c) L6H9
decreased the phosphorylation levels of MAPKs. NRK‐52E cells were pretreated with L6H9 and curcumin (Cur) 10 uM and then stimulated with
HG for 30 min, total proteins were extracted for western blot detection. (d–g) The effects of L6H9 on mRNA expression of renin (d), ACE (e), AT1
receptors (AT1) (f), and TGF‐β (g). NRK‐52E cells were pretreated with L6H9 and Cur and then stimulated with HG for 12 hr, total mRNAs were
extracted for real‐time qPCR assay. (h) The effects of L6H9 on production of ACE, TGF‐β, and collagen IV proteins. NRK‐52E cells were pretreated
with L6H9 and Cur and then stimulated with HG for 24 hr. Total protein was extracted for western blot analysis. (i) L6H9 reduced HG‐increased
Ang II level in cell medium. NRK‐52E cells were pretreated with L6H9 and Cur and then stimulated with HG for 24 hr. The media were collected
for ELISA detection. n = 5 independent experiments; bar graph shows mean values ± SEM; #P < .05, significantly different from DMSO group;
*P < .05, significantly different; ns = not significantly different from HG group
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2015), was used as a positive control. NRK‐52E cells were pretreated

of IRF3 and the subsequent expression of IFN‐inducible genes (Park

with L6H9, followed by incubation with HG (33 mM). Transient HG

et al., 2012). Considering that MAPKs are downstream of MyD88,

challenge (5‐min incubation) rapidly activated MD2/TLR4/MyD88

we only examined the MyD88 recruitment in this study. Collectively,

signalling pathway, which was illustrated by stronger interaction

these data showed that MD2 inhibitor L6H9 suppressed HG‐induced

between TLR4 and MD2 or MyD88 (Figures 2b and S1A–B). Pretreat-

RAS activation and TGF‐β expression through inhibition of the

ment with L6H9, inhibiting the binding of MD2 to TLR4, resulted in

TLR4/MyD88 signalling pathway.

reduced MyD88 recruitment to TLR4 (Figures 2b and S1A–B). For
the activation of the MAPK signalling pathways, downstream ofTLR4,
NRK‐52E cells were stimulated with HG for a slightly longer time
(30 min). Pretreatment of L6H9 decreased HG‐induced phosphorylation of ERK, JNK, and p38 in a dose‐dependent fashion (Figures 2c

3.3 | Both MyD88 silencing and MAPKs inhibition
suppressed HG‐induced RAS activation and TGF‐β
expression

and S1C–E). We then tested the effects of L6H9 on the expression
of genes involved in the RAS and fibrosis in NRK‐52E cells. As

As MD2/TLR4 mediates HG‐induced RAS activation, we assessed the

expected, L6H9 had minimal effect on HG‐stimulated renin expression

involvement of MyD88 and MAPKs, the classic downstream mole-

(Figure 2d). However, L6H9 dose dependently reduced the expression

cules of MD2/TLR4 signalling, in RAS activation. Knockdown of

of ACE, AT1 receptors, TGF‐β, and collagen IV either at the mRNA

MyD88 protein by siRNA in NRK‐52E cells showed no influence on

(Figure 2e–g) or protein (Figure 2h) levels. As a result, the amount of

HG‐increased renin mRNA level (Figure 3b). As expected, MyD88

Ang II released in the cultural medium from the cells was reduced

knockdown significantly decreased HG‐induced overexpression of

following L6H9 pretreatment (Figure 2i). Activated MD2/TLR4

ACE, AT1 receptors, and TGF‐β both at the mRNA and the protein

recruits two major adaptor molecules, MyD88 and TRIF. MyD88 acti-

levels (Figure 3c–e). As a result, HG‐induced increased Ang II level in

vates downstream pro‐inflammatory cascade through NF‐κB and

the media was significantly prevented by si‐MyD88 (Figure 3f).

MAPK pathways, while TRIF causes phosphorylation and activation

MAPKs constitute important downstream signalling pathways in the

FIGURE 3 MyD88 silencing and inhibition of MAPKs suppressed activation of RAS and expression of fibrotic factors, induced by high glucose
concentrations. (a) MyD88 knockdown in NRK‐52E cells by siRNA approach. Two si‐RNA sequences for MyD88 gene (si‐MyD88) were
transfected in NRK‐52E cells and the MyD88 protein levels were measured by western blot analysis (Ctrol: non‐transfected cells; NC: non‐MD2
scrambled transfection cells; two different siRNAs for MyD88 were used). (b–g) MyD88 silencing attenuated activation of RAS and MAPKs,
induced by high glucose ((HG; 33 mM) concentrations. NRK‐52E cells were firstly transfected with si‐MyD88 and then stimulated by HG
conditions for different times. (b–d) The mRNA levels of ACE, renin, and AT1 receptors (AT1) were detected by real‐time qPCR assay after 12‐hr
incubation of HG. (e) ACE and TGF‐β were detected by western blot with GAPDH as a loading control after 24‐hr incubation of HG. (f) The Ang II
levels in cultural medium were detected by ELISA after 24‐hr HG challenge. (g) The phosphorylation levels of MAPKs were detected by western
blot analysis after 30‐min HG incubation. n = 5 independent experiments; bar graph shows mean values ± SEM; #P < .05 significantly different
from NC group; *P < .05, significantly different; ns, not significantly different from HG group
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MD2/TLR4‐MyD88 signalling cascades. MyD88 knockdown also

The findings indicated that the development of DN was associated

prevented activation of downstream MAPKs signalling pathways

with elevated and activated MD2/TLR4 level in kidney tissue, and

induced by HG (Figures 3g and S2A–C). To further characterize the

the increased MD2 is mainly distributed in tubular cells.

roles of MAPKs in mediating MD2/TLR4‐dependent RAS activation,
we pretreated NRK‐52E cells with specific inhibitors of MAPKs,
including an ERK inhibitor PD98059, a p38 inhibitor SB203580 or a
JNK inhibitor SP600125, and then stimulated cells with HG for
12 hr. All three MAPK inhibitors exhibited marked inhibition of ACE
expression (Figure S3A–B), while only the ERK inhibitor showed significant inhibition of AT1 receptor expression (Figure S3C). All inhibitors suppressed HG‐induced expression of the fibrotic marker TGF‐β
(Figure S3A,D). As expected, none of them showed any effects on
HG‐induced renin mRNA production (Figure S3E), while all inhibitors
blocked HG‐increased Ang II release into the cell culture medium
(Figure S3F). These data further indicate that MyD88‐MAPKs mediates HG‐induced MD2/TLR4‐dependent RAS activation and TGF‐β
expression.

3.5 | MD2 KO inhibited RAS activation and
attenuated renal dysfunction in diabetic mice
STZ was used to develop Type 1 diabetes both in the MD2‐KO mice
and their wild‐type littermates (C57BL/6). The AT1 receptor antagonist, valsartan, was used as a comparison. During the 15‐week
follow‐up, body weight loss and hyperglycaemia were recorded in diabetic groups. Neither MD2 KO nor valsartan affected serum glucose
level and body weight (Figure S6A–B). Renal function was assessed
by renal haemodynamics and biochemical markers. Either MD2‐KO
or valsartan prevented the increases of kidney/body weight ratio,
serum creatinine, urinary albumin, and urinary albumin/creatinine
ratio in diabetic mice (Figure 5a–d). In MD2‐KO mice, both values of
renal blood flow velocity (left kidney vein) and the systolic/diastolic

3.4 | MD2 is up‐regulated and activated in diabetic
mouse kidney
The results obtained so far indicated a relationship of MD2 with the
pathogenesis of DN. We then evaluated the level of MD2 in the
kidneys of mice with STZ‐induced diabetes. Mice were treated with
a single i.p. injection of STZ to induce Type 1 diabetes and then were
fed with standard diet for 2 or 4 months to develop nephropathy (see
Section 2). The results showed that, compared with the non‐diabetic
control mice, levels of MD2 and TLR4 protein in diabetic mouse
kidney gradually increased with the development of DN (from 2 to
4 months; Figure 4a). Similar results were observed at the level of
mRNA (Figure 4b,c). We next evaluated MD2 localization in kidney tissue. Tubular cells, podocytes, and infiltrated macrophages are very
important in the development of DN. We carried out immunofluorescent double staining using MD2 antibody and cell‐type specific
markers to identify MD2‐expressing renal cell types in diabetic mice.
Consistent with our in vitro data, MD2 expression was detected
mainly in AQP‐1‐positive tubular cells (Figure 4d), with much less in
F4/80‐positive infiltrated macrophages and no expression seen in
WT1‐positive podocytes (Figures S4 and S5). One of the limitations

pressure ratio were comparable to those of control WT mice (Figure
S7A–B), indicating the preservation of normal renal haemodynamics.
These data indicate improved renal function in the diabetic mice following MD2‐KO or RAS blockade.
We then determined the RAS profile in these animals. Figure 5e
showed that the local Ang II level was significantly increased in the
STZ‐induced diabetic mouse kidney, and this increase was prevented
in the MD2‐KO mice. As an antagonist of AT1 receptors, valsartan
did not affect local levels of Ang II in mouse kidney (Figure 5e).
Hyperglycaemia induced only slight increase in serum Ang II level
and MD2‐KO also reversed this change (Figure 5f). Further analysis
demonstrated that kidneys from MD2‐KO mice with diabetes, had
lower expression of RAS‐related transcripts, including ACE and AT1
receptors, compared to the WT diabetic mice (Figure 5g). As expected,
MD2‐KO did not block diabetes‐induced renin production (Figure 5g).
Similar results were obtained for expression of ACE protein, using
western blot analysis (Figures 5h and S8A). Consistent with the in vitro
data, the diabetes‐augmented phosphorylation and activation of ERK,
JNK, and p38 were prevented in the MD2‐KO mice (Figures 5h and
S8B–D). These data indicate the regulation of RAS activation by
MD2 in the kidneys of diabetic animals.

in this work is that we are unable to confirm all MD2‐expressing cell
types in mouse kidneys. We performed the mechanistic studies only
in cultured kidney epithelial cells. Although these data showed that

3.6 | MD2 KO attenuated diabetic renal fibrosis in
mice

renal tubular cells expressed MD2, we fully noted that analysis of
other kidney cell types is important. We anticipate that other cell

Histological analysis of kidney tissue showed histological abnormali-

types in kidney tissues including mesangial cells and infiltrated T cells

ties, fibrosis, and mesangial expansion in WT diabetic mice (Figures 6a

may also utilize this signalling pathway. However, this possibility

and S9A–C). However, these changes were absent in MD2‐KO mice

requires confirmation in the future. In addition to protein expression,

with diabetes (Figures 6a and S9A–C). Histological abnormalities and

the formation of MD2/TLR4 complex reflects the activation of

fibrosis in diabetic mice were also ameliorated by valsartan treatment

MD2/TLR4 signalling. Thus, we evaluated the interaction of MD2

(Figures 6a and S9A–C). These results were further confirmed by the

and TLR4 in diabetic mouse kidney using the method of immunopre-

analysis of fibrotic markers such as collagen IV, CTGF, TGF‐β, and

cipitation. As shown in Figure 4e, the amounts of MD2/TLR4 complex

MMP2 at either protein or at mRNA levels. MD2 KO significantly

in diabetic kidney gradually increased with the development of DN.

reduced STZ‐induced overexpression of fibrotic proteins in mouse
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FIGURE 4 MD2 is overexpressed and activated in diabetic mouse kidney. Mice were treated with a single i.p. injection of STZ to induce Type 1
diabetes and then were fed with standard diet for 2 or 4 months to develop nephropathy. Kidney tissues were collected at the time of killing.
(a) Representative western blot of MD2 and TLR4 proteins in kidney tissues. Densitometric quantification is shown in right (n = 7 mice per group).
(b and c) Real‐time qPCR assay of MD2 and TLR4 mRNAs in kidney tissues (n = 7 mice per group). (d) Kidney tissue sections from each group were
double‐stained with MD2 and AQP‐1 immunofluorescence antibodies (with DAPI staining for nuclei). Representative images from n = 7 per group
were shown. Scale bar: 20 μm. White arrows indicate fluorescence‐positive MD2 protein. (e) MD2 is activated in diabetic kidney. Shown are
representative western blots (IBs) from the co‐precipitation (IPs) studies for MD2/TLR4 complex formation. Densitometric quantification is shown
in right (n = 7 mice per group). Bar graph shows mean values ± SEM; *P < .05, significantly different as indicated
kidney (Figures 6b–c, and S10A–C). In addition, MD2 KO attenuated

diabetes, compared with those from WT diabetic mice, suggesting

Bax expression and increased Bcl‐2 in the kidneys in diabetes

prevention of diabetes‐induced macrophage infiltration into the renal

(Figures 6c and S10D–E). Immunohistochemical staining confirmed

tissue (Figure S11A). The mRNA analysis of renal tissue lysate demon-

reduction of TNF‐α and CD68 in kidneys from MD2‐KO mice with

strated that MD2‐KO mice were resistant to the increased expression
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FIGURE 5 MD2 knockout attenuated diabetes‐induced renal damage and inhibited activation of RAS in mice. MD2 knockout mice (KO),
valsartan (Val) ‐treated C57BL/6 mice, and their wild‐type control (WT) developed diabetes (DM), 4 months after STZ injection. (a–e) Kidney/
body weight ratio (a), serum creatinine (b), urinary albumin (c), urinary albumin/creatinine ratio (d), Ang II level in kidney tissues (e), and Ang II level
in serum (f) were detected by corresponding kits. (g) The kidney tissue mRNA for ACE, renin, and AT1 receptors were determined by real‐time
qPCR assay and normalized to β‐actin. (h) Representative western blot analysis of ACE and phosphorylated MAPKs in kidney tissues. Bar graph
shows mean values ± SEM; n = 8 mice per group, *P < .05, significantly different as indicated; ns = not significant. WT‐Ctrl, wild‐type non‐diabetic
mice; WT‐DM, wild type diabetic mice; WT‐DM + Val valsartan‐treated diabetic mice; KO‐Ctrl, MD2 knockout nondiabetic mice; KO‐DM, MD2
knockout diabetic mice

of inflammatory cytokines (TNF‐α and IL‐6) and adhesion molecule

levels, but the kidney to body weight ratio was significantly reduced

(ICAM‐1; Figure S11B–D), induced by diabetes. These results showed

(Figure S13A–C). Histological analysis showed that diabetes‐induced

that MD2 gene KO effectively inhibited activation of the renal

structural alterations and glycogen accumulation were prevented by

TLR4/MAPKs‐RAS pathway and attenuated renal injury in Type 1

the treatment with L6H9 (Figure 7a). L6H9 decreased the phosphory-

diabetic mice.

lation and activation of MAPKs, including ERK, JNK, and p38, in diabetic kidneys (Figures 7b and S14A–C). Co‐immunoprecipitation
revealed that L6H9 blocked the interaction between TLR4 and MD2

3.7 | Treatment with the MD2 inhibitor L6H9
attenuated DN in mice

in vivo, which led to less MyD88 recruited to TLR4 (Figures 7c and
S14D–E). As a result, L6H9 inhibited RAS activation in kidneys by
reducing diabetes‐induced Ang II elevation (Figure 7d) and renal

To further validate MD2 as a therapeutic target for the treatment

expression of ACE/AT1 receptors (Figures 7e–f and S14F). As

of DN in vivo, we studied the pharmacological effects of the

expected, L6H9 did not suppress renin expression during diabetes

MD2 inhibitor, L6H9, in Type 1 diabetic mice. Administration of

(Figure 7e). Also, L6H9 decreased the inflammatory responses in

L6H9 for 4 months in normal mice did not induce tubular injury,

kidneys of diabetic mice (Figure S15A–F). NF‐κB is a downstream

inflammation, serum creatinine up‐regulation, or renal dysfunction,

transcriptional factor of the MD2/TLR4 pro‐inflammatory signalling

indicating the safety of L6H9 itself (Figure S12A–F). In diabetic mice,

pathway and we have therefore measured IκBα phosphorylation, as

L6H9 treatment did not alter body weight and blood glucose

a marker of NF‐κB activation. The results showed that either L6H9
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FIGURE 6 MD2 knockout decreased diabetes‐induced fibrosis in mouse kidney. MD2 knockout mice (KO), valsartan (Val)‐treated C57BL/6
mice, and their wild‐type control (WT) developed diabetes (DM), 4 months after STZ injection. (a) Representative light micrograph of
histochemical assessment of kidney tissues: haematoxylin and eosin (H&E) staining, PAS for glycogen (purple), Masson's trichrome stain (Blue) for
detection of connective tissue, and Sirius red staining were used for the detection of fibrosis (Red); 400× magnification; scale bar: 50 μm.
(b) Kidney tissue content of fibrotic genes was determined by real‐time quantitative‐PCR for collagen 1, CTGF, and TGF‐β. Bar graph shows mean
values ± SEM; n = 8 mice per group, *P < .05, significantly different as indicated. (c) Representative western blot analysis of indicated proteins in
kidney tissues
administration or MD2 KO prevented IκBα phosphorylation in STZ‐

activation and nephropathy, accompanied with decreased inflamma-

induced diabetic mouse kidneys (Figure S16).

tion (Figure 8).
MD2 and the TLR4 signalling pathway are critically important for
LPS‐induced inflammation in innate immunity. Recent studies have

4

|

DISCUSSION

highlighted the critical role of TLR4 in the progression of DN
(Kuwabara et al., 2012; Wada & Makino, 2016). TLR4 is highly

Although DN is known to be strongly linked to the local activation of

expressed in human renal tubules and its expression is further up‐

the RAS, less is known about the regulation of RAS components by

regulated by HG (Tang & Lai, 2012). HG‐induced TLR4 activation

hyperglycaemia. Our study documented for the first time the role of

further triggers IL‐6 and CCL2 expression via MAPKs and NF‐κB

MD2/TLR4 in up‐regulating renal ACE/ AT1 receptor expression and

activation, leading to interstitial macrophage infiltration, albuminuria,

Ang II production and renal dysfunction driven by hyperglycaemia.

and renal dysfunction (Lin et al., 2012). TLR4‐KO mice displayed resis-

Briefly, the major findings of this work demonstrate that MD2/TLR4

tance to renal phenotypes in mice with STZ‐induced diabetes (Jialal,

complex is activated under HG conditions, which trigger MyD88‐

Major, & Devaraj, 2014). Although previous studies indicated that

dependent activation of MAPKs, contributing to local ACE/ AT1

inhibition of the TLR4 signalling pathway has potential therapeutic

receptor gene expression and Ang II production and subsequent

implications in DN, few studies have focused on the function of the

fibrosis in kidneys. Either genetic deletion or pharmacological inhibi-

MD2 component, in diabetic renal diseases. It is expected that MD2,

tion of MD2 has a protective effect on diabetes‐induced renal RAS

with TLR4 together, is able to regulate renal inflammation in diabetic
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FIGURE 7 Oral administration of the MD2 inhibitor L6H9 ameliorated diabetic (DM)‐induced kidney damage in C57BL/6 mice.
(a) Representative light micrograph of histochemical assessment of kidney tissues: haematoxylin and eosin (H&E) staining, Masson's trichrome
staining, and PAS staining for detection of connective tissue; 400× magnification. (b) Representative western blot analysis of phosphorylated
MAPKs in kidney tissues; n = 3 mice in each group. (c) Representative co‐immunoprecipitation analysis of TLR4‐MD2 and TLR4‐MyD88 bindings
in kidney tissues; n = 3 mice in each group. (d) Serum Ang II level was detected by corresponding kit. (e) Kidney tissue content of RAS‐related
genes was determined by real‐time quantitative‐PCR assay. (f) Representative western blot analysis of ACE in kidney tissues; n = 3 mice in each
group. Bar graph shows mean values ± SEM; n = 8 in four groups, #P < .05, significantly different from Control group; *P < .05, significantly
different from DM group; ns = not significantly different from DM group
mice. Our previous study has shown that L6H9 can prevent glucose‐

Further, MD2 was significantly overexpressed and activated in dia-

induced inflammation in heart‐derived H9c2 cells (Zhong et al.,

betic mouse kidney tissues (Figure 4). MD2‐KO mice were resistant

2015). In the present study, we found that MD2 was required for

to diabetes‐induced renal inflammation and macrophage infiltration,

HG‐induced TLR4 activation and that HG induced the formation

and treatment with the MD2 inhibitor L6H9, significantly decreased

of the MD2/TLR4 complex and that MD2 inhibition significantly

inflammatory cytokine production in diabetic mouse kidney. Thus,

blocked the recruitment of MyD88 and MAPKs phosphorylation.

the first finding of this work is the validation of the role of MD2 in
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catalyses the conversion of angiotensinogen into the decapeptide
angiotensin I which is then converted into the octapeptide Ang II by
ACE. In diabetes, the increased renal levels of Ang II stimulate TGF‐β
expression and fibrosis in kidney to enhance the development of DN
(Kinoshita et al., 2011; Morsy, Heeba, & Mahmoud, 2015). Although
the RAS is classically activated by reduced glomerular blood flow,
which may be caused by loss of sodium and water or by renal artery
narrowing, local RAS can be directly activated by hyperglycaemia,
independent of a haemodynamic stimulus (Singh, Singh, Alavi, &
Leehey, 2003; Vidotti et al., 2004; Xiao, Wang, Yang, Liu, & Sun,
2013). In keeping with previous studies, we found that HG treatment
increases renin, angiotensinogen, ACE, and Ang II levels in cultured rat
glomerular mesangial cells (Singh et al., 2003; Vidotti et al., 2004).
However, the mechanism for hyperglycaemia‐induced generation of
Ang II remains unaddressed. Here, we observed that inhibition of
MD2/TLR4 signalling blocked HG‐increased expression of ACE/ AT1
receptor genes, but not renin, suggesting that the MD2/TLR4 pathway regulates part of the RAS cascade without affecting upstream
FIGURE 8 Scheme of the possible mechanisms of the involvement
of MD2 in activation of the RAS and inflammation, induced by high‐
glucose (HG) and the renal injury in diabetes. AT1, AT1 receptors

renin production and secretion. Renin is a cAMP‐inducible gene. The
cAMP response element‐binding protein cascade and members of
the nuclear receptor superfamily have been reported to regulate renin
transcription (Castrop et al., 2010). Under the condition of HG or diabetes, Visavadiya et al. showed that HG induces renin overexpression

mediating TLR4 pro‐inflammatory signalling activation in the patho-

via phosphorylation of cAMP response element‐binding protein in

genesis of DN.

human renal proximal tubular HK‐2 cells (Visavadiya, Li, & Wang,

Second, we demonstrated a new correlation between MD2/TLR4

2011). Studies also suggest that the GPR91 (succinate) receptor may

innate immunity signalling and RAS activation in diabetic kidney. In

be of relevance for the stimulation of renin release in response to

HG‐stimulated tubular epithelial cells, MD2/MyD88‐MAPKs seem to

HG levels (Toma et al., 2008) or in experimental diabetes (Vargas,

serve as important upstream regulators of ACE and AT1 receptor

Toma, Kang, Meer, & Peti‐Peterdi, 2009). However, these suggestions

expression. Blockage of MD2/TLR4 signalling pathway significantly

await further work to confirm their relevance.

suppressed HG‐induced ACE and AT1 receptor expression and Ang II

Given the important role of MD2/TLR4 in innate immunity and

production both in vitro and in vivo, which contributes to the attenu-

inflammation, this study provides a new link between the RAS and

ation of DN. A large number of studies have revealed a forward

immunity, and presents MD2 as an important target that regulates

crosstalk between Ang II and TLR4 (Dange et al., 2014; Lv, Chen, Shao,

both local RAS and inflammation in diabetic kidneys. It still remains

Chen, & Shi, 2015). Ang II is able to activate MD2/TLR4 as well as its

unclear to as how hyperglycaemia activates MD2. Apart from LPS,

downstream signalling cascade (Nair, Ebenezer, Saini, & Francis, 2015).

several other ligands have been recently reported to bind MD2

TLR4 has been considered a receptor‐like protein for Ang II, mediating

and activate the MD2/TLR4 pathway (Adanitsch et al., 2014;

the pro‐inflammatory and pro‐oxidative effects of Ang II in cardiovas-

Aranda et al., 2014; Hussein, Liu, Skwarczynski, & Toth, 2014). Thus,

cular (Dange et al., 2014; Nakashima et al., 2015) and kidney diseases

an important and unsolved question remains as to the specific

(Lv et al., 2015; Lv, Jia, Yang, Zhu, & Ding, 2009). Our previous study

mechanism by which hyperglycaemia promotes MD2/TLR4 complex

also found that MD2 mediated Ang II‐induced inflammation through

formation and TLR4 activation under hyperglycaemic conditions.

direct interaction with Ang II in cardiomyocytes (Han et al., 2017).

Delineation of such pathways will contribute to a better understand-

However, the MD2/TLR4 innate immunity system and the RAS may

ing of the pathogenesis of DN.

be mutually regulated in DN. Here, we identified the MD2‐TLR4/

In summary, we have demonstrated that hyperglycaemia can acti-

MyD88 pathway as an important upstream signalling pathway for

vate the MD2/TLR4‐MyD88‐MAPKs signalling cascade to induce

the production of Ang II under hyperglycaemic conditions. This is the

ACE and AT1 receptor expression and Ang II production, as well as

second finding of this work, indicating a reverse crosstalk between

inflammation, in both tubular cells and diabetic mouse kidneys

Ang II and the MD2/TLR4 signalling pathway.

(Figure 8). We have identified a role of MD2 in modulating local RAS

During diabetes, regulation of the renal RAS seems to be indepen-

activation in kidney to stimulate renal dysfunction and fibrosis in dia-

dent of the circulating RAS, and local renal Ang II levels has been

betes. Our findings provide evidence that pharmacological inhibition

found to be several‐fold higher than that in plasma (Seikaly, Arant, &

of MD2 may be considered as a therapeutic approach to prevent or

Seney, 1990). The pathway starts with pro‐renin production in the

mitigate DN and that the low MW inhibitor L6H9 could be a potential

juxtaglomerular cells of kidney (Nguyen & Muller, 2010). Renin

candidate for such therapy.
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